Log In
Saturday 22nd October 2016

NICE issues guidance on rimonabant

25th June 2008

The National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of rimonabant for the treatment of overweight and obese patients.

The guidance recommends:

  • rimonabant as an addition to diet and exercise for adults who are obese or overweight and who have had an inadequate response to, are intolerant of or are contraindicated to orlistat and sibutramine.
  • rimonabant treatment should be continued beyond 6 months only if the person has lost at least 5% of their initial body weight since starting rimonabant treatment.
  • rimonabant treatment should be discontinued if a person returns to their pre-treatment weight.
  • rimonabant treatment should not be continued for longer than 2 years without a formal clinical assessment and discussion of the individual risks and benefits with the person receiving treatment.

Andrew Dillon, NICE Chief Executive and Executive Lead for the guideline said:

“The independent advisory committee recommended rimonabant, along with diet and exercise, as a treatment option for adults who are obese or overweight. This is good news for patients for whom orlistat and sibutramine are not effective.

“Being overweight or obese can lead to a range of serious health problems, including heart disease, type 2 diabetes, osteoarthritis and some cancers. These recommendations should be used in conjunction with the NICE guideline ‘Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children' published in December 2006��?


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Article Information

Title: NICE issues guidance on rimonabant
Author: Martine Hamilton
Article Id: 7317
Date Added: 25th Jun 2008



Recent Related Articles

Guidance to protect lone working nurses

NICE approves new cancer drugs

Children's behavioural issues may be linked to common painkiller


Add to scrapbook
Show Comments
Add comment
Find all related articles

M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2016